drugset / Trial / NCT00575913

Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study

NCT00575913

Phase 4 Completed 118 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess, under daily practice conditions, the safety profile and the efficacy of a new formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

Timeline

Start
2003-09
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Alfuzosin Small molecule 10 mg

Indications